rethinkMushrooms Search
Menu
Home / Reishi — Ganoderic Acids & Triterpenes
Guide

Ganoderic Acids and Cancer: Specific Anti-Tumor Research

Ganoderic acids target cancer cells through four distinct mechanisms. The 2024 data on immunotherapy and drug resistance changes the picture. Here's what the research shows.

RethinkMushrooms Research TeamUpdated 15 min read

Reishi — Ganoderic Acids & Triterpenes

4 distinct anti-tumor mechanisms

Ganoderic acids kill cancer cells through four separate pathways: apoptosis, autophagy, anti-angiogenesis, and transcription factor suppression. A 2024 study found one of them also enhances the efficacy of immune checkpoint therapy.

Chen et al., Toxicol Appl Pharmacol, 2024; Wang et al., Life, 2024

5+ cancer types

breast, lung, liver, brain, cervical studied

2024 breakthrough

GA-T enhances checkpoint immunotherapy

Drug resistance

GA-D reverses gemcitabine resistance in TNBC

Chen et al., Toxicol Appl Pharmacol, 2024; Wang et al., Life, 2024

Illustration of ganoderic acid compounds from reishi mushroom targeting cancer cell mechanisms including apoptosis and autophagyView as image ↗

In 2024, Chen and colleagues published a finding that hadn't appeared in the ganoderic acid literature before: ganoderic acid T doesn't just kill cancer cells directly. It modifies the environment around them in a way that makes immune checkpoint therapy more effective. In laboratory models, combining GA-T with checkpoint therapy produced greater tumor suppression than either treatment alone.[4]

That's a different class of finding than "this compound is toxic to cancer cells in a dish." It's evidence that a natural reishi compound could work alongside modern cancer immunotherapy, not just instead of it.

This article covers the ganoderic acid cancer research in full, including the 2024 immunotherapy and drug resistance data that no competitor has reported. It also includes the honest counterpoint: most of this evidence is from laboratory cell cultures and animal models. Human clinical trial evidence for ganoderic acids specifically in cancer remains limited, and any discussion of these compounds in that context needs to be clear about that gap. For a broader introduction to ganoderic acids and what they are, see Ganoderic Acids: The Unique Triterpenes in Reishi. For the reishi overview, see What Is Reishi Mushroom? The Science Behind the Mushroom of Immortality.

Key Takeaways

  • Ganoderic acids have demonstrated anti-tumor activity against breast, lung, liver, brain, cervical, and esophageal cancer cells in laboratory studies
  • Four distinct mechanisms are involved: apoptosis (programmed cell death), autophagy (cellular self-digestion), anti-angiogenesis (cutting off blood supply), and suppression of cancer survival signaling through NF-kB and AP-1
  • In 2024, GA-T was found to enhance immune checkpoint therapy efficacy by modulating the tumor microenvironment through galectin-1 downregulation
  • In 2024, GA-D was found to reverse gemcitabine resistance in triple-negative breast cancer cells by disrupting tumor glycolysis via HIF-1α destabilization
  • Ganoderic acid DM is the most extensively studied anticancer ganoderic acid, with evidence across lung, prostate, colon, and breast cancer models
  • A 2025 GRADE-assessed meta-analysis found insufficient clinical trial evidence to claim cancer treatment efficacy in humans; the preclinical evidence is robust but clinical translation remains early

Four Ways Ganoderic Acids Kill Cancer Cells

Ganoderic acids have demonstrated anti-cancer activity in laboratory studies against breast, lung, liver, brain, colon, cervical, and esophageal cancer cells. They work through four mechanistically distinct pathways, each representing a separate way of eliminating cancer cells or preventing them from spreading.

Apoptosis is programmed cell death, a process cancer cells have evolved mechanisms to avoid. Several ganoderic acids reactivate this pathway by shifting the balance of pro-death and pro-survival proteins inside cancer cells, increasing Bax and caspase activity while suppressing Bcl-2.

Autophagy is a separate cell-death mechanism where a cell digests its own components. Some cancer cells are resistant to apoptosis but vulnerable to autophagy. Ganoderic acid DM and ganoderic acid D trigger autophagic cell death specifically, which matters for cancers that have developed resistance to apoptosis-inducing drugs.

Anti-angiogenesis means cutting off the blood supply that tumors need to grow beyond a certain size. Rather than directly killing cancer cells, this approach starves them. Ganoderic acid fractions from reishi suppress two key angiogenesis signals: VEGF (vascular endothelial growth factor) and TGF-beta1.

Transcription factor suppression targets the signaling systems cancer cells use to drive their own proliferation and invasion. Ganoderic acids suppress NF-kB and AP-1, two proteins that act as master switches for cancer survival and spread.

A 2024 comprehensive review by Wang and colleagues in the journal Life confirmed at least 14 distinct biological activities for ganoderic acids overall, with anti-cancer effects operating across multiple pathways simultaneously.[1]

Ganoderic Acid A: From Breast Cancer to Glioblastoma

Ganoderic acid A is the most abundant and most-studied member of the family, and it shows up in the research across an unusually wide range of cancer types.

In triple-negative breast cancer, Yang and colleagues demonstrated in 2018 that GA-A inhibits JAK2 (Janus kinase 2) phosphorylation and blocks the downstream signaling of STAT3, a protein that drives tumor cell invasion.[5] Triple-negative breast cancer (TNBC) lacks the receptor targets that hormone-based therapies rely on, making it one of the harder subtypes to treat. The JAK2/STAT3 pathway is one of the primary survival mechanisms TNBC cells use. GA-A's inhibition of that pathway in this study was accompanied by measurably reduced MMP-9 activity, a protein the cancer cells use to degrade surrounding tissue and invade new sites.[5]

Jiang and colleagues had already shown in 2008 that a ganoderic acid fraction suppresses breast cancer cell proliferation and invasion through a different pair of targets: AP-1 (activator protein-1) and NF-kB, two transcription factors that cancer cells use to drive their own growth and resist immune attack.[6] The fact that GA-A hits JAK2/STAT3 while the broader ganoderic acid fraction hits AP-1/NF-kB suggests these compounds are working through complementary, not overlapping, mechanisms in breast cancer.

In liver cancer, Wang and colleagues showed in 2017 that GA-A inhibited proliferation and invasion in hepatocellular carcinoma cells and triggered apoptosis via a Bax/Bcl-2 shift, increasing the pro-death protein and decreasing the pro-survival one.[7]

In glioblastoma (brain cancer), GA-A triggered both apoptosis and autophagy simultaneously, while also inactivating the PI3K/AKT survival pathway.[8] The Cheng and Xie 2019 study in the Journal of Biochemical and Molecular Toxicology found that GA-A increased caspase-3, caspase-9, and Bax while suppressing Bcl-2, a consistent apoptosis signature. Glioblastoma is one of the most treatment-resistant brain cancers, and any compound that activates multiple cell-death pathways simultaneously is worth tracking.

Structurally related compounds extend the picture further. Liu and colleagues demonstrated in 2015 that GA-A, GA-I, and GA-J all induced apoptosis in HeLa cervical cancer cells through a reactive oxygen species mechanism, generating oxidative stress that overwhelmed the cancer cells' antioxidant defenses.[9]

Separately, Jia and colleagues produced semi-synthetic amide derivatives of GA-A in 2023 that showed greater anticancer potency than the natural compound by specifically targeting the p53-MDM2 interaction, the protein pairing that cancer cells often use to deactivate the p53 tumor suppressor.[10] This positions natural GA-A as a pharmaceutical scaffold for drug development, not just a finished bioactive compound.

Ganoderic Acid DM: The Broadest Anticancer Profile

Ganoderic acid DM is the compound that has attracted the most pharmaceutical interest across the widest range of cancer types.

Bryant and colleagues' 2017 review in the Journal of Clinical and Cellular Immunology described GA-DM as the most extensively studied anticancer ganoderic acid, with demonstrated inhibitory effects in lung, prostate, colon, and breast cancer models.[2] The review identified GA-DM as the strongest candidate for pharmaceutical development among the ganoderic acid family, partly because of its broad spectrum activity and partly because it engages both apoptotic and autophagic pathways.

The autophagy mechanism was confirmed specifically in non-small cell lung cancer (NSCLC) by Xia and colleagues in 2020.[11] GA-DM inhibited the PI3K/Akt/mTOR signaling cascade in NSCLC cells, triggering autophagic flux. When the researchers blocked autophagy pharmacologically, the cytotoxic effect of GA-DM was significantly reduced, confirming that autophagy is the primary mechanism, not a secondary effect. This is an important distinction: it means GA-DM is specifically relevant to cancer cell populations that have developed resistance to apoptosis-inducing treatments.

For anyone comparing ganoderic acids as potential pharmaceutical candidates, GA-DM's combination of broad cancer type coverage and dual-pathway activity makes it the compound most frequently cited in the drug development literature.

Ganoderic Acid T and the Immunotherapy Surprise

Ganoderic acid T has an older story and a new one that changes the framing entirely.

The older story: Tang and colleagues showed in 2006 that GA-T induces apoptosis in lung cancer cells via the mitochondrial pathway.[3] The mechanism involved cytochrome-c release from mitochondria and activation of caspase-3, but not caspase-8, which is the signature of intrinsic (mitochondria-driven) apoptosis rather than death-receptor-driven apoptosis. This was one of the landmark early papers establishing that individual ganoderic acids, not just reishi extracts generally, have cell-specific anti-tumor activity.

The new story: Chen and colleagues published data in 2024 in Toxicology and Applied Pharmacology showing GA-T does something none of the other ganoderic acid cancer studies had shown.[4] It modulates the tumor microenvironment by downregulating galectin-1, a protein that cancer cells use to suppress immune responses in their vicinity.

Galectin-1 works as a kind of immunological cloaking device. Cancer cells secrete it to dampen the T-cell response that would otherwise attack them. When Chen's team reduced galectin-1 levels using GA-T, the tumor became more visible to the immune system. Combined with paclitaxel (a standard chemotherapy drug), GA-T significantly enhanced tumor suppression over either treatment alone. Combined with immune checkpoint therapy, the effect was even more pronounced: greater tumor suppression than checkpoint therapy by itself.[4]

Checkpoint immunotherapy works by removing brakes on the immune system's anti-tumor response. The problem is that some tumors still evade this by creating an immunosuppressive local environment. GA-T's galectin-1 suppression addresses exactly that evasion mechanism. This makes it a potentially meaningful combination candidate rather than a standalone treatment.

This finding is absent from every consumer reishi and ganoderic acid article currently ranking. It appeared in 2024, it changes the mechanistic framing of GA-T from "cytotoxic compound" to "immunotherapy sensitizer," and it represents the direction the more interesting cancer research is heading. For population-level context on mushrooms and cancer, see Mushroom Consumption and Cancer Risk Reduction: Meta-Analysis of Population Studies.

Ganoderic Acid D: Reversing Drug Resistance in Breast Cancer

One of the persistent problems in cancer treatment is that tumor cells evolve to become resistant to the drugs that initially worked against them. Ganoderic acid D addresses this problem through a metabolic route.

Shao and colleagues showed in 2020 that GA-D induces autophagic cell death (rather than apoptosis) in esophageal squamous cell carcinoma cells.[12] The cell death was not blocked when apoptosis inhibitors were added, confirming that GA-D's mechanism is autophagy-dependent. This matters because esophageal squamous cell carcinoma frequently develops resistance to apoptosis-based treatments.

In 2024, Luo and colleagues published data in Phytomedicine with a directly clinically relevant finding: GA-D reversed gemcitabine resistance in triple-negative breast cancer cells.[13] Gemcitabine is one of the standard chemotherapy agents used in TNBC when other options fail. Resistance to it is a significant clinical problem.

The mechanism GA-D used to reverse that resistance was metabolic: it inhibited HIF-1alpha (hypoxia-inducible factor 1-alpha), a protein that cancer cells upregulate to shift their energy production toward glycolysis (the Warburg effect). By destabilizing HIF-1alpha, GA-D disrupted the alternative energy pathway that resistant TNBC cells rely on to survive gemcitabine treatment. Cells that lost their glycolytic advantage became vulnerable again.[13]

This mechanism is distinct from everything GA-A, GA-DM, or GA-T does. It's not about inducing apoptosis or autophagy in cancer cells; it's about removing the metabolic shielding that makes them drug-resistant. The uniqueness of the target (cancer-cell glycolysis) positions GA-D as a potential combination partner with existing chemotherapy rather than a replacement.

Anti-Angiogenesis: Cutting Off the Tumor's Blood Supply

Cancer cells can only grow beyond a few millimeters if they recruit new blood vessels to supply nutrients and oxygen. This process, angiogenesis, is driven by specific signaling proteins that the tumor secretes.

Stanley and colleagues demonstrated in 2005 that Ganoderma extract suppresses the two main angiogenic signals from prostate cancer cells: VEGF (vascular endothelial growth factor) and TGF-beta1.[14] The anti-angiogenic effect was attributed to the triterpene (ganoderic acid) fraction, not the polysaccharide fraction, establishing that the bitter, alcohol-extractable compounds in reishi are responsible for this activity.

Anti-angiogenesis is mechanistically separate from direct cytotoxicity. Direct cytotoxicity kills existing cancer cells. Anti-angiogenesis prevents the tumor from building the infrastructure it needs to grow and metastasize. Compounds that do both address cancer through fundamentally different biological targets, which is why combination approaches are of interest in pharmaceutical research. For the broader comparison of ganoderic acids versus polysaccharides, see How Reishi Triterpenes Differ from Polysaccharides in Mechanism.

The Honest Picture: What the Clinical Evidence Actually Shows

The research described in this article is almost entirely preclinical. Cell culture studies and animal models demonstrate that ganoderic acids can kill cancer cells through specific mechanisms. This is important science. It is not the same as showing these compounds treat cancer in humans.

Jeitler and colleagues published a narrative review in Frontiers in Pharmacology in 2020 covering medicinal mushrooms in integrative oncology.[15] Their assessment of reishi: the preclinical anti-cancer evidence is robust, but human RCT evidence remains limited. They recommended considering reishi as a complementary approach within an integrative oncology framework, not as a primary cancer treatment.

The most rigorous current assessment comes from Jafari and colleagues' 2025 GRADE-assessed systematic review and meta-analysis of Ganoderma clinical trials in Food Science and Nutrition.[16] The GRADE framework evaluates not just whether an effect was observed but whether the quality of the evidence supporting it is sufficient to act on clinically. The finding for cancer: insufficient evidence to claim cancer treatment efficacy in humans. The finding for lipid-lowering effects: moderate-quality evidence.

This gap between preclinical and clinical evidence is real and worth naming plainly. Cell culture studies show cancer cells dying from ganoderic acid exposure. Animal models show tumor growth inhibition. No human RCT has confirmed that ganoderic acids reduce tumor burden, extend survival, or meaningfully improve outcomes in cancer patients.

The 2024 data on GA-T and immunotherapy, and GA-D and drug resistance, represents the direction that makes clinical translation conceivable. Compounds that work alongside existing therapies rather than replacing them face a lower evidence bar for clinical utility. But those studies are still cell culture data, and the path from cell culture to clinical reality in oncology is long and frequently disappointing.

For the broader Reishi cancer research picture, see Reishi and Cancer: What 50 Years of Research Tells Us. For the Reishi bioactive compound overview, see Reishi Bioactive Compounds: Triterpenes, Polysaccharides, and Sterols.

The Bottom Line

Ganoderic acids from reishi target cancer cells through four distinct mechanisms: apoptosis, autophagy, anti-angiogenesis, and transcription factor suppression. The most studied compounds are GA-A (broadest cancer type range, including TNBC and glioblastoma), GA-DM (widest spectrum across cancer types, strongest pharmaceutical candidate), GA-T (lung cancer, and a 2024 finding showing it enhances immune checkpoint therapy), and GA-D (esophageal cancer, and 2024 evidence for reversing gemcitabine resistance in TNBC). The evidence base is large and mechanistically sophisticated. The clinical limitation is equally clear: no human RCT has confirmed cancer treatment efficacy for ganoderic acids specifically, and a 2025 GRADE-assessed meta-analysis found the clinical evidence insufficient to support cancer treatment claims.

Frequently Asked Questions

Sources & References

  1. 1RTHM-02014·Wang, Siyi et al. (2024). “Research Progress on the Biological Activity of Ganoderic Acids in Ganoderma lucidum over the Last Five Years..” Life (Basel.Study breakdown →PubMed →↩
  2. 2RTHM-00852·Bryant, John Matthew et al. (2017). “Anticancer Activity of Ganoderic Acid DM: Current Status and Future Perspective..” Journal of clinical & cellular immunology.Study breakdown →PubMed →↩
  3. 3RTHM-00201·Tang, Wen et al. (2006). “Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells..” Life sciences.Study breakdown →PubMed →↩
  4. 4RTHM-01869·Chen, Suyu et al. (2024). “Ganoderic acid T, a Ganoderma triterpenoid, modulates the tumor microenvironment and enhances the chemotherapy and immunotherapy efficacy through downregulating galectin-1 levels..” Toxicology and applied pharmacology.Study breakdown →PubMed →↩
  5. 5RTHM-01021·Yang, Yuguang et al. (2018). “Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway..” Oncology letters.Study breakdown →PubMed →↩
  6. 6RTHM-00258·Jiang, Jiahua et al. (2008). “Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling..” International journal of molecular medicine.Study breakdown →PubMed →↩
  7. 7RTHM-00927·Wang, Xu et al. (2017). “Ganoderic acid A inhibits proliferation and invasion, and promotes apoptosis in human hepatocellular carcinoma cells..” Molecular medicine reports.Study breakdown →PubMed →↩
  8. 8RTHM-01043·Cheng, Yong et al. (2019). “Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway..” Journal of biochemical and molecular toxicology.Study breakdown →PubMed →↩
  9. 9RTHM-00721·Liu, Ru-Ming et al. (2015). “Structurally related ganoderic acids induce apoptosis in human cervical cancer HeLa cells: Involvement of oxidative stress and antioxidant protective system..” Chemico-biological interactions.Study breakdown →PubMed →↩
  10. 10RTHM-01712·Jia, Yi et al. (2023). “Ganoderic Acid A and Its Amide Derivatives as Potential Anti-Cancer Agents by Regulating the p53-MDM2 Pathway: Synthesis and Biological Evaluation..” Molecules (Basel.Study breakdown →PubMed →↩
  11. 11RTHM-01303·Xia, Junbo et al. (2020). “Ganoderic acid DM induces autophagic apoptosis in non-small cell lung cancer cells by inhibiting the PI3K/Akt/mTOR activity..” Chemico-biological interactions.Study breakdown →PubMed →↩
  12. 12RTHM-01285·Shao, Chang-Sheng et al. (2020). “Ganoderic acid D induces synergistic autophagic cell death except for apoptosis in ESCC cells..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
  13. 13RTHM-01940·Luo, Binbin et al. (2024). “Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization..” Phytomedicine : international journal of phytotherapy and phytopharmacology.Study breakdown →PubMed →↩
  14. 14RTHM-00087·Stanley, Gwenaelle et al. (2005). “Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells..” Biochemical and biophysical research communications.Study breakdown →PubMed →↩
  15. 15RTHM-00622·Jeitler, Michael et al. (2020). “Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review..” Frontiers in pharmacology.Study breakdown →PubMed →↩
  16. 16RTHM-02098·Jafari, Ali et al. (2025). “The Nutritional Significance of Ganoderma lucidum on Human Health: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials..” Food science & nutrition.Study breakdown →PubMed →↩